From Yahoo Finance: 2025-05-12 23:12:00

The stock market saw a surge after the US and China agreed to a 90-day tariff truce, with the Nasdaq up 4.85%, S&P 500 up 3.26%, and Dow Jones up 2.81%. ImmunityBio Inc. (IBRX) saw a 14.01% increase in share price due to a 41,192% revenue spike driven by strong Anktiva performance in treating non-muscle invasive bladder cancer. CEO Richard Adcock highlighted a new marketplace for their therapies. IBRX ranks 9th on the list of top performers today, but AI stocks are seen as having higher return potential in a shorter time frame.



Read more at Yahoo Finance: Why ImmunityBio, Inc. (IBRX) Soared Today